glp-1 receptor agonists effects on cardiovascular risk reduction Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction GLP-1 receptor agonists (GLP-1RAs): cardiovascular
Description
doi: 10.3390/cells11132023
Each additional compound introduces its own side effect profile, interaction potential, and pharmacokinetic considerations
Two of the most promising medications currently available for weight loss are semaglutide GLP-1 (sold under the brand names Wegovy and Ozempic) and Zepbound (containing tirzepatide )
Regulatory bodies like the European Medicines Agency (EMA) are actively facilitating the approval of new GLP-1 therapies, which is expected to drive market expansion
Ed.) 2017;357:j2499
